Dolan Matthew Vincent 4
4 · DEXCOM INC · Filed May 16, 2024
Insider Transaction Report
Form 4
DEXCOM INCDXCM
Dolan Matthew Vincent
EVP, Strategy & Corporate Dev
Transactions
- Sale
Common Stock
2024-05-15$126.58/sh−2,423$306,703→ 40,075 total
Footnotes (2)
- [F1]On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- [F2]Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025 and 121 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan.